Top-Rated StocksTop-RatedNASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis $1.87 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cabaletta Bio Stock (NASDAQ:CABA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cabaletta Bio alerts:Sign Up Key Stats Today's Range$1.81▼$2.0150-Day Range$1.87▼$4.9152-Week Range$1.76▼$26.35Volume4.64 million shsAverage Volume1.59 million shsMarket Capitalization$91.41 millionP/E RatioN/ADividend YieldN/APrice Target$27.30Consensus RatingBuy Company OverviewCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More… A “Thank You Gift” From Pres. Trump - Genius (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Cabaletta Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks41st Percentile Overall ScoreCABA MarketRank™: Cabaletta Bio scored higher than 41% of companies evaluated by MarketBeat, and ranked 689th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCabaletta Bio has only been the subject of 4 research reports in the past 90 days.Read more about Cabaletta Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.31) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.59% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 1.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.59% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 1.85%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News Sentiment0.07 News SentimentCabaletta Bio has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.Search Interest5 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows16 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 129% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Cabaletta Bio is held by insiders.Read more about Cabaletta Bio's insider trading history. Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Stock News HeadlinesCabaletta Bio (NASDAQ:CABA) Discloses Promising Clinical Data from ACR Convergence 2024 ConferenceOn November 18, 2024, Cabaletta Bio, Inc. released pivotal information from the American College of Rheumatology (ACR) Convergence 2024 conference. The November 22 at 5:03 AM | americanbankingnews.comCabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024November 22 at 2:13 AM | msn.comA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 24, 2024 | Colonial Metals (Ad)Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024November 20, 2024 | nasdaq.comCabaletta Bio Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCabaletta Bio (NASDAQ:CABA) Price Target Cut to $12.00 by Analysts at Wells Fargo & CompanyNovember 19, 2024 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Given "Buy" Rating at HC WainwrightNovember 19, 2024 | americanbankingnews.comCabaletta Bio Reveals CABA-201's Positive Clinical Safety And Efficacy DataNovember 18, 2024 | markets.businessinsider.comSee More Headlines CABA Stock Analysis - Frequently Asked Questions How have CABA shares performed this year? Cabaletta Bio's stock was trading at $22.70 on January 1st, 2024. Since then, CABA shares have decreased by 91.8% and is now trading at $1.87. View the best growth stocks for 2024 here. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01. When did Cabaletta Bio IPO? Cabaletta Bio (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Top institutional shareholders of Cabaletta Bio include Jennison Associates LLC (11.53%), Fred Alger Management LLC (8.43%), Geode Capital Management LLC (2.24%) and State Street Corp (1.83%). Insiders that own company stock include Steven Nichtberger, Anup Marda, Gwendolyn Binder and Catherine Bollard. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings8/08/2024Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$27.30 High Stock Price Target$50.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,359.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.10% Return on Assets-45.49% Debt Debt-to-Equity RatioN/A Current Ratio8.11 Quick Ratio8.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.53Miscellaneous Outstanding Shares48,880,000Free Float44,048,000Market Cap$91.41 million OptionableOptionable Beta2.42 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:CABA) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.